Skip to content
Peptide research

IGF-1 DES

Also known as Des(1-3) IGF-1
Category
Growth Hormone
Administration routes
Injectable
Regulatory status
Not FDA-approved

A truncated form of IGF-1 marketed to bodybuilders for tenfold anabolic potency and muscle hyperplasia. The potency edge is real biochemistry, but data is almost entirely animal-based; human evidence is essentially absent, with no safety profile established. The headline risk is severe hypoglycemia (seizures, unconsciousness, death), plus an unresolved concern it could fuel existing tumors. Not FDA-approved; supply is unregulated research-grade product.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

IGF-1 DES (Des(1-3)IGF-1) is a naturally occurring shortened version of insulin-like growth factor 1 (IGF-1) that is missing the first three amino acids of the full 70-amino-acid molecule. This small change has a dramatic effect: it reduces binding to the body's IGF carrier proteins by about 99%, leaving the peptide essentially 'unbound' and free to act on cells directly. As a result, IGF-1 DES is roughly 10 times more potent than regular IGF-1 at stimulating cell growth and muscle protein synthesis. It has been found naturally in bovine colostrum, human brain tissue, and porcine uterus.

How it works in the body

A truncated version of IGF-1 missing the first 3 amino acids. This makes it 10x more potent because it binds much more weakly to some IGF binding proteins (IGFBPs) that normally sequester IGF-1. Free to act immediately, it activates IGF-1 receptors on muscle cells, triggering the PI3K/Akt pathway for protein synthesis and cell growth.

Research overview

IGF-1 DES research spans three decades, beginning with its identification as a natural byproduct of IGF-1 processing in the body. The core mechanism — drastically reduced binding to carrier proteins while keeping full ability to activate the IGF-1 receptor — was established in the mid-1990s. Animal studies have shown enhanced growth effects in growth hormone-deficient mice, accelerated gut recovery after surgical resection in rats, and modulation of muscle cell signaling. It activates the same cell growth pathway (PI3K/Akt/mTOR) as regular IGF-1, which drives muscle protein synthesis, satellite cell activation, and anti-wasting effects. However, nearly all IGF-1 DES data comes from animal models and cell culture studies. No controlled human clinical trials have been conducted on this specific peptide. It remains a research tool, not an approved therapeutic agent.

Who researches IGF-1 DES?

Commonly researched by

  • People exploring muscle growth and performance

    Researched for potential effects on lean mass, strength, or athletic performance.

  • People exploring tissue repair and injury recovery

    Studied for effects on wound healing, tendon/ligament repair, or recovery from injury.

  • People researching GI and digestive health

    Studied for gastrointestinal protection, gut lining repair, or digestive support.

Important considerations for

  • Those with Active cancer

    Absolute

    IGF-1 DES is 10x more potent than regular IGF-1. Directly promotes tumor cell proliferation.

  • Those with Diabetic retinopathy

    High

    Potent IGF-1 activity worsens proliferative retinopathy.

  • Those with Hypoglycemia-prone individuals

    High

    Potent glucose-lowering effect. Risk of dangerous hypoglycemia, especially when fasted.

Safety & interactions

Do not use if

  • Active cancer

    Absolute

    IGF-1 DES is 10x more potent than regular IGF-1. Directly promotes tumor cell proliferation.

  • Diabetic retinopathy

    High

    Potent IGF-1 activity worsens proliferative retinopathy.

  • Hypoglycemia-prone individuals

    High

    Potent glucose-lowering effect. Risk of dangerous hypoglycemia, especially when fasted.

How to read the ratings

Benefits
= confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High · Moderate · Low · Theoretical
Interactions
= direction with this peptide: Protective / Synergistic · Caution · Neutral

Risk summary(8)

Rated by level of concern

  • Severe hypoglycemia — IGF-1 DES has insulin-like glucose-lowering effects that can cause seizures, loss of consciousness, brain damage, and death, particularly when combined with insulin or fasting

    High

    FDA prescribing information for Increlex (mecasermin): hypoglycemia warning, dosing-with-food requirement, contraindication to dosing without a meal. IGF-1 glucose-lowering physiology.

  • Cancer risk — The IGF-1/IGF1R signaling pathway promotes cell proliferation and survival; elevated IGF-1 is epidemiologically linked to breast, prostate, colorectal, and lung cancers; a potent IGF-1R agonist could accelerate existing tumor growth

    Moderate

    Increlex (mecasermin) FDA label, contraindication for active or suspected neoplasia; IGF-1 and cancer-risk epidemiology (Endogenous Hormones and Breast Cancer Collaborative Group pooled analysis and subsequent Mendelian randomization work). Lung-cancer linkage is the least well supported element.

  • Organ enlargement (organomegaly) — Animal studies show dose-dependent increases in kidney, heart, liver, lung, and stomach weights (Gillespie et al., 1990)

    Moderate

    Rodent infusion studies of des(1-3)IGF-I / LR3IGF-I reporting dose-dependent organ weight increases (Tomas FM, Read LC, Ballard FJ and colleagues, J Endocrinol / Biochem J, roughly 1990-1993). PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=des(1-3)IGF-I+organ+weight+rat

  • Suppression of endogenous GH/IGF-1 axis — Exogenous IGF-1 administration may suppress natural growth hormone secretion via negative feedback

    Moderate

    Human rhIGF-1 infusion studies demonstrating GH suppression via pituitary and hypothalamic feedback (Hartman ML and colleagues, J Clin Endocrinol Metab, early 1990s); IGF-1 negative-feedback physiology. Author attribution is descriptive; the underlying human finding is well established.

  • Product quality concerns — Research-grade peptides lack pharmaceutical manufacturing controls; products may contain wrong sequences, contaminants, degradation products, or no active peptide

    High

    FDA position that research-grade peptides are not approved for human use and are not manufactured under GMP; published analyses of content variability and endotoxin contamination in grey-market peptide products (cited descriptively).

  • No established human safety profile — All Des(1-3)IGF-1 data is preclinical; adverse effects in humans are unknown and unpredictable

    High

    No registered human trials of Des(1-3)IGF-1 identified on ClinicalTrials.gov: https://clinicaltrials.gov/search?term=des(1-3)IGF-1.

  • Injection site reactions — Localized pain, swelling, or lipohypertrophy at injection sites

    Low

    Increlex (mecasermin) FDA label, adverse reactions including injection-site lipohypertrophy and local reactions, plus site-rotation guidance.

  • Potential acromegalic effects — Chronic IGF-1R activation may cause abnormal tissue growth patterns similar to acromegaly

    Theoretical

    Acromegaly pathophysiology (IGF-1-mediated tissue overgrowth); no reported cases of acromegalic change with exogenous IGF-1 analogs.

Interaction summary(8)

Rated by direction with this peptide

  • Insulin (all types)

    CautionHigh

    Additive glucose-lowering. IGF-1 analogs and insulin both drive peripheral glucose uptake, and the mecasermin label directs dose reduction of insulin and close glucose monitoring when the two are used together, making severe hypoglycemia the most likely serious event with this pairing. Extrapolated to Des(1-3)IGF-1, which has no human data of its own but escapes IGFBP buffering and would be expected to act faster.

    Increlex (mecasermin) FDA prescribing information: hypoglycemia warning and instruction to adjust concomitant antidiabetic agents.

  • Insulin secretagogues and other oral antihyperglycemics (sulfonylureas, meglitinides, GLP-1 agonists)

    CautionModerate

    Same additive hypoglycemia mechanism as insulin but generally less abrupt; the mecasermin label directs dose adjustment of concomitant antidiabetic agents. Sulfonylureas and meglitinides are the real risk within this group because their insulin release is not glucose-dependent. GLP-1 receptor agonists carry little intrinsic hypoglycemia risk on their own and are the weakest member of this grouping — they matter mainly as one more glucose-lowering influence added on top.

    Increlex (mecasermin) FDA prescribing information, direction to adjust concomitant antidiabetic therapy; established class pharmacology of secretagogues vs incretin agents.

  • Growth hormone / GH secretagogues (CJC-1295, ipamorelin, sermorelin, tesamorelin)

    SynergisticModerate

    GH raises endogenous IGF-1 and IGFBP-3 while Des(1-3)IGF-1 adds IGFBP-independent receptor activation, so the two together would be expected to add to total IGF-1R signaling — synergistic for the intended anabolic effect but equally so for organ growth, fluid retention, insulin resistance and any proliferative risk. Entirely mechanism-based: no human combination study exists, and none of these secretagogues has been studied alongside any IGF-1 analog.

    GH/IGF-1 axis physiology. Mechanism-based inference only; no human combination studies identified.

  • Glucocorticoids (prednisone, dexamethasone)

    CautionLow

    Glucocorticoids induce muscle catabolism and IGF-1 resistance, directly opposing the anabolic effect sought here — rodent work used dexamethasone-induced catabolism specifically as the model des(1-3)IGF-I was tested against. They also raise blood glucose, which blunts rather than worsens hypoglycemia risk while steroids are on board, so the practical hazard is loss of efficacy plus a possible unmasking of hypoglycemia as steroids taper. The dominant consequence is reduced effect, not direct harm.

    Rat dexamethasone-catabolism models treated with des(1-3)IGF-I (Read/Tomas group); glucocorticoid-induced IGF-1 resistance literature. Descriptive citation, not individually verified.

  • Active or suspected malignancy, and IGF-1R-targeted oncology therapy

    CautionHigh

    Active or suspected neoplasia is a labeled contraindication for recombinant IGF-1, and giving a potent IGF-1R agonist to a patient with a known or suspected tumor — or one being treated with IGF-1R blocking antibodies or TKIs — is directly pharmacologically antagonistic to the therapy as well as potentially tumor-promoting. Note this is a clinical-state and drug-class caution rather than a studied drug-drug interaction.

    Increlex (mecasermin) FDA label, contraindicated in active or suspected neoplasia; IGF-1R inhibitor oncology pharmacology.

  • Beta-blockers (non-selective and selective)

    CautionModerate

    Beta-blockade blunts the adrenergic warning symptoms of hypoglycemia — tremor, palpitations, anxiety — so a falling glucose can progress toward confusion or seizure without the usual early cues. The effect is best documented for non-selective agents and is weaker with cardioselective ones; sweating is generally preserved. This is a general hypoglycemia-unawareness caution applied here, not an IGF-1-specific finding, but it matters more with an unbuffered fast-acting analog.

    Established beta-blocker and hypoglycemia-unawareness pharmacology (documented largely with insulin and sulfonylureas; applied here by class mechanism).

  • Alcohol and prolonged fasting or carbohydrate restriction

    CautionModerate

    Alcohol suppresses hepatic gluconeogenesis and fasting depletes glycogen, removing the two defenses the body uses against an IGF-1-driven glucose drop; the mecasermin label's requirement to dose with food exists for exactly this reason.

    Increlex (mecasermin) FDA label dosing-with-food requirement; established alcohol suppression of gluconeogenesis.

  • Thiazolidinediones and other insulin sensitizers

    CautionTheoretical

    Improved insulin sensitivity would be expected to lower the threshold at which an IGF-1 analog produces symptomatic hypoglycemia — additive rather than synergistic, manageable with monitoring, and worth counting only when several glucose-lowering influences act together. TZDs and metformin do not cause hypoglycemia on their own. Severity reduced from Low to Theoretical: this is a mechanism-based extension with no direct study of any kind.

    Mechanism-based extension of the labeled instruction to adjust antihyperglycemic agents with mecasermin. No direct study; this is an inference.

Known risks(8)

  • Severe hypoglycemia — IGF-1 DES has insulin-like glucose-lowering effects that can cause seizures, loss of consciousness, brain damage, and death, particularly when combined with insulin or fasting

  • Cancer risk — The IGF-1/IGF1R signaling pathway promotes cell proliferation and survival; elevated IGF-1 is epidemiologically linked to breast, prostate, colorectal, and lung cancers; a potent IGF-1R agonist could accelerate existing tumor growth

  • Organ enlargement (organomegaly) — Animal studies show dose-dependent increases in kidney, heart, liver, lung, and stomach weights (Gillespie et al., 1990)

  • Suppression of endogenous GH/IGF-1 axis — Exogenous IGF-1 administration may suppress natural growth hormone secretion via negative feedback

  • Product quality concerns — Research-grade peptides lack pharmaceutical manufacturing controls; products may contain wrong sequences, contaminants, degradation products, or no active peptide

  • No established human safety profile — All Des(1-3)IGF-1 data is preclinical; adverse effects in humans are unknown and unpredictable

  • Injection site reactions — Localized pain, swelling, or lipohypertrophy at injection sites

  • Potential acromegalic effects — Chronic IGF-1R activation may cause abnormal tissue growth patterns similar to acromegaly

Drug interactions(5)

  • Insulin (all forms)

    High

    Additive hypoglycemic effect — both compounds lower blood glucose through overlapping mechanisms. Concurrent use significantly increases risk of severe hypoglycemia. Only experienced users with glucose monitoring should consider combination.

  • Oral hypoglycemic agents (metformin, sulfonylureas, thiazolidinediones)

    Moderate to High

    Potential additive glucose-lowering effect. Des(1-3)IGF-1 may potentiate hypoglycemia risk in diabetic patients on oral medications.

  • Growth hormone (GH/HGH)

    Moderate

    GH stimulates hepatic IGF-1 production. Combining exogenous Des(1-3)IGF-1 with GH may produce supraphysiological IGF-1R activation, increasing risks of organomegaly and metabolic disruption. No safety data exist for the two together.

  • Other IGF-1 analogues (IGF-1 LR3, mecasermin)

    High

    Additive IGF-1R stimulation. Combining multiple IGF-1 receptor agonists could amplify both anabolic effects and adverse effects including hypoglycemia and cancer risk.

  • Corticosteroids

    Low to Moderate

    Corticosteroids suppress IGF-1 signaling and promote muscle catabolism. Concurrent use may partially counteract Des(1-3)IGF-1 effects, but the net metabolic impact is unpredictable.

Research & benefits

Evidence base

Evidence Level
Preclinical only
Total Studies
6
Human Studies
0

All direct evidence for Des(1-3)IGF-1 comes from in vitro cell culture studies and in vivo animal models (rodents). No controlled human clinical trials have been conducted on Des(1-3)IGF-1 specifically. The broader IGF-1 system is well-studied in humans, but systemic IGF-1 supplementation in elderly subjects failed to augment muscle strength or protein synthesis (Adams, 2001). Des(1-3)IGF-1 clinical applications have not yet been evaluated in humans.

Researched for(5)

Rated by confidence in the evidence

  • Enhanced anabolic potency (~10x over native IGF-1)

    Medium

    Extensive animal and cell studies show up to 10-fold greater potency; no human trials exist.

    Ballard FJ, Francis GL, Ross M and colleagues on in vitro potency of des(1-3)IGF-I vs IGF-I in L6 myoblasts; Tomas FM and colleagues, rodent infusion studies (Biochem J / J Endocrinol, 1987-1993). Descriptive citation only. PubMed record set: https://pubmed.ncbi.nlm.nih.gov/?term=%22des(1-3)IGF-I%22

  • Muscle hyperplasia and satellite cell activation

    Speculative

    Extrapolated from general IGF-1 muscle biology; no analog-specific or human studies confirm this.

    Extrapolated from the general IGF-I satellite-cell literature (e.g. Musaro/Rosenthal mIGF-1 transgenic mouse work); no Des(1-3)IGF-1-specific hyperplasia study identified. PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=IGF-1+satellite+cell+hyperplasia

  • Reduced IGFBP sequestration for greater bioavailability

    Medium

    Binding studies confirm reduced IGFBP affinity; greater bioavailability in humans is inferred, not measured.

    IGFBP binding-affinity characterization of des(1-3)IGF-I (Francis GL, Ross M, Ballard FJ and colleagues, J Mol Endocrinol / Biochem J, late 1980s-1990s). Descriptive citation. PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=des(1-3)IGF-I+binding+protein+affinity

  • Selective anabolic effects on gut tissue recovery

    Low

    Rat studies show disproportionate intestinal growth; no human trials in gut injury or recovery.

    Read LC / Steeb CB / Howarth GS rat intestinal growth and gut-injury studies with des(1-3)IGF-I and LR3IGF-I (Am J Physiol Gastrointest Liver Physiol, J Endocrinol, roughly 1992-1998). Descriptive citation; no PMID verified. PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=des(1-3)IGF-I+intestine

  • PI3K/Akt/mTOR pathway activation for protein synthesis

    Low

    Well-established receptor signaling pathway; direct evidence for this specific analog is sparse.

    Established IGF-1R/PI3K/Akt/mTOR signaling literature in skeletal muscle (Rommel C et al., Nat Cell Biol 2001, on IGF-1-induced myotube hypertrophy via PI3K/Akt/mTOR and PI3K/Akt/GSK3). No Des(1-3)IGF-1-specific human signaling data exists.

Benefits(5)

  • Enhanced anabolic potency (~10x over native IGF-1)

    Ballard et al. (1996) demonstrated ~10-fold greater potency at stimulating hypertrophy and proliferation of cultured cells due to reduced IGFBP binding. Gillespie et al. (1990) confirmed enhanced potency in vivo in GH-deficient lit/lit mice.

  • Muscle hyperplasia and satellite cell activation

    IGF-1 signaling activates satellite cell proliferation and differentiation, which is obligatory for muscle hypertrophy (Adams, 2001; Yoshida & Delafontaine, 2020). Des(1-3)IGF-1 may promote localized hyperplasia via enhanced receptor activation.

  • Reduced IGFBP sequestration for greater bioavailability

    Des(1-3)IGF-1 retains only ~1% of native IGF-1 affinity for IGFBPs, meaning more free peptide reaches target receptors (Ballard et al., 1996). Yang et al. (1999) showed IGF-1 treatment reduced IGFBP-3 levels 3-fold in porcine muscle cells.

  • Selective anabolic effects on gut tissue recovery

    Lemmey et al. (1991) showed des(1-3)IGF-1 at 0.96 mg/kg/day was as effective as high-dose IGF-1 (2.4 mg/kg/day) in promoting weight gain and nitrogen retention after 80% gut resection in rats.

  • PI3K/Akt/mTOR pathway activation for protein synthesis

    Yoshida & Delafontaine (2020) reviewed IGF-1 activation of PI3K/Akt/mTOR and PI3K/Akt/GSK3beta pathways, increasing protein synthesis while inhibiting FoxO-mediated protein degradation in skeletal muscle.

Key studies(6)

  1. Ballard FJ, Wallace JC, Francis GL, Read LC, Tomas FM

    International Journal of Biochemistry and Cell Biology

    1996

    Des(1-3)IGF-I is about 10-fold more potent than IGF-I at stimulating hypertrophy and proliferation of cultured cells, due to reduced binding to IGFBPs caused by absence of glutamate at position 3. Selective anabolic effects are particularly evident in gut tissues.

  2. Enhanced potency of truncated insulin-like growth factor-I (des(1-3)IGF-I) relative to IGF-I in lit/lit mice

    Animal study (in vivo)Multiple groups of GH-deficient lit/lit mice3 weeks daily injections

    Gillespie C, Read LC, Bagley CJ, Ballard FJ

    Journal of Endocrinology

    1990

    Des(1-3)IGF-I at 3 mcg/day was as effective as 30 mcg/day IGF-I at increasing body length. The lower DES dose increased kidney and heart weights; higher doses of either peptide also increased liver, lung and stomach weights, confirming greater in vivo potency of the truncated form.

  3. IGF-I and the truncated analogue des-(1-3)IGF-I enhance growth in rats after gut resection

    Animal study (in vivo)Multiple groups of 170g rats7 days post-surgery

    Lemmey AB, Martin AA, Read LC, Tomas FM, Owens PC, Ballard FJ

    American Journal of Physiology

    1991

    Des(1-3)IGF-I at 0.96 mg/kg/day produced weight gains of 20.8g (vs 14.0g controls) over the final 3 days, comparable to high-dose IGF-I (2.4 mg/kg/day, 21.9g). Enhanced nitrogen retention indicated reduced muscle protein breakdown.

  4. Effect of IGF-I and Des(1-3)IGF-I on IGFBP-3 and IGFBP-3 mRNA in cultured porcine embryonic muscle cells

    In vitro cell culturePorcine embryonic myogenic cell cultures24-hour treatments

    Yang F, Johnson BJ, White ME, Hathaway MR, Dayton WR

    Journal of Cellular Physiology

    1999

    Both IGF-I and Des(1-3)IGF-I at 20 ng/ml produced a 3-fold reduction in IGFBP-3 in conditioned media. IGF-I caused a 7-fold decrease in IGFBP-3 mRNA and a 4-fold increase in myogenin mRNA, linking differentiation to reduced IGFBP-3.

  5. Yoshida T, Delafontaine P

    Cells

    2020

    IGF-1 increases skeletal muscle protein synthesis via PI3K/Akt/mTOR and PI3K/Akt/GSK3beta pathways, inhibits FoxO-mediated E3 ubiquitin ligase transcription, and activates satellite cells for muscle regeneration. IGF-1 signaling is suppressed in many chronic disease states.

  6. Adams GR

    Western Journal of Medicine

    2001

    IGF-I mediates GH growth-promoting effects and functions via autocrine-paracrine mechanisms in muscle. Satellite cell activation by IGF-I is obligatory for hypertrophy. However, doubling circulating IGF-I in elderly subjects had no effect on muscle protein synthesis or strength. Elevated IGF-I linked to prostate, colorectal, and lung cancers.

Regulation & availability

Why researchers look at it

Removing just three amino acids from natural IGF-1 makes it ~10x more potent by freeing it from binding proteins that normally sequester 99% of the full-length molecule. Cell and animal studies confirm enhanced muscle protein synthesis and satellite cell activation. No controlled human trial has ever been conducted, and broader IGF-1 supplementation studies in elderly subjects failed to augment muscle strength — the gap between theoretical potency and demonstrated real-world benefit remains wide.

FDA status
Not FDA-approved for any indication. IGF-1 DES has no ATC code assigned and carries no legal drug status in most jurisdictions. The FDA has approved mecasermin (recombinant human IGF-1, brand name Increlex) for severe primary IGF-1 deficiency, but this is the full-length 70-amino-acid IGF-1, not the truncated Des(1-3) form. Des(1-3)IGF-1 has never undergone FDA review or clinical development for any therapeutic application.
WADA status
PROHIBITED at all times (in-competition and out-of-competition). IGF-1 DES (Des(1-3)IGF-1) falls under WADA Prohibited List category S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics. All IGF-1 variants, analogues, and mimetics are explicitly banned. This status is unchanged in the 2026 WADA Prohibited List. Detection methods include mass spectrometry-based assays capable of identifying synthetic IGF-1 analogues in blood and urine. Athletes testing positive face sanctions ranging from 2 to 4 years of competition ban.
Prescribability
No — IGF-1 DES is not FDA-approved for any therapeutic indication and is not available by prescription.
Availability
IGF-1 DES is not available through pharmacies or by prescription. Products sold through unregulated channels may contain incorrect peptide sequences, degradation products, contaminants, or no active peptide. IGF-1 DES is prohibited by WADA and is not approved by the FDA, EMA, or Health Canada for human therapeutic use.

International status

  • EU

    Not approved

  • US

    Not FDA-approved

  • Worldwide

    No regulatory approval in any jurisdiction

Regulatory timeline(8)

  1. 1987
    Des(1-3)IGF-1 first characterized as a naturally occurring truncated form of IGF-1 isolated from bovine colostrum and human brain tissue (CAS 112603-35-7 registered)
  2. 1990
    Gillespie et al. publish enhanced potency data in GH-deficient mice, establishing ~10x potency advantage over native IGF-1
  3. 1991
    Lemmey et al. demonstrate efficacy in rat gut resection recovery model, showing therapeutic potential for catabolic states
  4. 1996
    Ballard et al. publish comprehensive review in Int J Biochem Cell Biol establishing key properties: ~1% IGFBP affinity, ~10x potency, selective gut tissue effects
  5. 2005
    FDA approves mecasermin (recombinant full-length IGF-1) as Increlex for severe primary IGF-1 deficiency — Des(1-3)IGF-1 not included
  6. 2004-present
    WADA includes all IGF-1 variants (including Des(1-3)IGF-1) on the Prohibited List under S2 category, banned at all times
  7. 2020s
    No pharmaceutical company has initiated clinical development. FDA has not reviewed Des(1-3)IGF-1 for any indication
  8. 2026
    Status unchanged: no FDA approval, no clinical trials registered, remains on WADA 2026 Prohibited List.

Sources & FAQs

Research sources(6)

  1. PubMed — National Library of Medicine (https://pubmed.ncbi.nlm.nih.gov/)
  2. PubMed Central (PMC) — Free full-text archive (https://pmc.ncbi.nlm.nih.gov/)
  3. WADA Prohibited List 2026 (https://www.wada-ama.org/en/prohibited-list)
  4. USADA — IGF-1 and the WADA Prohibited List (https://www.usada.org/spirit-of-sport/igf-1-and-the-world-anti-doping-agency-prohibited-list/)
  5. Wikipedia — Des(1-3)IGF-1 (https://en.wikipedia.org/wiki/Des(1-3)IGF-1)
  6. ScienceDirect — Des(1-3)IGF-I: a truncated form of insulin-like growth factor-I (https://www.sciencedirect.com/science/article/abs/pii/1357272596000568)

Frequently asked questions(6)

How does IGF-1 DES differ from regular IGF-1?

IGF-1 DES (Des(1-3)IGF-1) is missing the first three amino acids (Gly-Pro-Glu) from IGF-1's N-terminus. This truncation reduces binding to IGF binding proteins (IGFBPs) to ~1% of native affinity, while preserving full IGF-1 receptor affinity. The result is approximately 10-fold greater bioactive potency because the peptide avoids sequestration by binding proteins.

How does IGF-1 DES differ from IGF-1 LR3?

IGF-1 LR3 has an arginine substitution at position 3 and a 13-amino-acid extension; its human half-life is unestablished. IGF-1 DES is shorter (67 amino acids vs 83 for LR3), has a half-life of 20-30 minutes, and acts more locally at injection sites. Both share reduced IGFBP binding.

Is IGF-1 DES naturally occurring?

Yes. Des(1-3)IGF-1 is an endogenous protein produced by post-translational cleavage of native IGF-1. It has been isolated from bovine colostrum, human brain tissue, and porcine uterus (Ballard et al., 1996).

Are there any human clinical trials on IGF-1 DES?

No. As of 2026, no controlled human clinical trials have been conducted specifically on Des(1-3)IGF-1. All direct evidence comes from animal studies and cell culture experiments. The broader IGF-1 system is well-studied in humans, but Des(1-3)IGF-1 has never undergone clinical development.

Can IGF-1 DES cause cancer?

There is no direct evidence that Des(1-3)IGF-1 causes cancer, but the IGF-1 signaling pathway is directly implicated in cancer biology. Epidemiological studies show elevated IGF-1 levels are associated with increased risk of breast (OR 1.28), prostate (OR 1.31), and colorectal cancers. Chronic use of a potent IGF-1R agonist like Des(1-3)IGF-1 could theoretically accelerate growth of existing or dormant tumors.

Is IGF-1 DES legal?

IGF-1 DES occupies a regulatory gray zone. It is not a controlled substance in most countries but is not approved for human use by any major regulatory agency. It is explicitly banned by WADA under category S2 (Peptide Hormones, Growth Factors) at all times, in and out of competition.